Archive · 25 Sep 2026
Lord's Mark Advances AI Breast Screening Toward Final Trials
Lord's Mark and C-MET are developing a wearable device to help screen for breast cancer.
The device uses heat sensors and artificial intelligence to look for unusual temperature patterns.
It is designed to work without radiation and can run on a battery.
The company says trials in India have been completed and accurately identified the cases tested.
More Phase 2 trials are planned in India, the USA, Europe and Great Britain from January 2027.
The Technical Committee has approved final trials, subject to local rules.
Regulators are still reviewing the technology and its results.
If testing and approvals succeed, the company hopes to place the product commercially in April 2027.
Lord's Mark Industries and C-MET are advancing an AI-powered, radiation-free wearable breast cancer screening device toward final clinical trials.
The battery-operated device uses thermal sensors and AI-based temperature mapping to identify abnormal temperature patterns.
Phase 2 trials targeting 98% accuracy are scheduled to begin in January 2027 across India, the USA, Europe and Great Britain.
Indian clinical trials have been completed, while regulatory evaluation and CDSCO approval remain in progress.
The company is targeting key clinical and regulatory milestones before March 2027 and commercial placement by April 2027, subject to approvals.
- Who
- Lord's Mark Industries Limited and the Centre for Materials for Electronic Technology developed the technology, with Managing Director Sachidanand Upadhyay commenting on the project.
- What
- An AI-powered, radiation-free wearable breast cancer screening device is moving toward final clinical trials.
- When
- Phase 2 trials are scheduled to begin in January 2027; the company targets regulatory milestones before March 2027 and commercial placement by April 2027.
- Where
- Trials and regulatory work involve India, the United States, Europe and Great Britain.
- Why
- The technology is intended to identify breast cancer-related abnormalities and expand affordable screening access, subject to clinical validation and regulatory approval.
- Technology
- A battery-operated wearable using thermal sensors and AI-based temperature mapping.
- Radiation
- The device is designed to screen without radiation.
- Completed testing
- The company says clinical trials in India accurately identified the cases evaluated.
- Planned trials
- Phase 2 trials targeting 98% accuracy are scheduled to begin in January 2027.
- Regulatory status
- Evaluation is ongoing in India, with CDSCO approval in process; requirements for other markets are also being pursued.
- Target milestones
- Lord's Mark is targeting completion of final trials and key regulatory milestones before March 2027.
- Commercial target
- Commercial placement is targeted for April 2027, subject to clinical validation and applicable approvals.
